fosphenytoin
Trade name: Cerebyx
Approved
Aug 5, 1996
Fosphenytoin, also known as fosphenytoin sodium, and sold under the brand name Cerebyx among others, is a water-soluble phenytoin prodrug that is administered intravenously to deliver phenytoin, potentially more safely than intravenous phenytoin. It is used in the acute treatment of convulsive status epilepticus. — Wikipedia
Clinical trial activity
13 trials · 19 clinical orgs · 21 marketing orgs
Earliest trial started Jul 1, 2007 (NCT00510783)
Timeline
1990s
- Jun 4, 1991
Orphan Drug Designation
- Aug 5, 1996
Parke-Davis — Earliest FDA Approval
- Aug 5, 1996
Parke-Davis — NDA Organization
- Aug 5, 1996
Parke-Davis — NDA Secondary Org
- Aug 5, 1996
Warner Lambert — NDA Secondary Org
2000s
- Aug 6, 2007
Atlantide Pharmaceuticals — Marketing Organization
- Aug 6, 2007
Sankyo — Marketing Organization
- Aug 6, 2007
Apotex — Marketing Organization
- Aug 6, 2007
Fresenius — Marketing Organization
- Aug 6, 2007
Hospira — Marketing Organization
- Aug 6, 2007
Lutipold — Marketing Organization
- Aug 6, 2007
Teva — Marketing Organization
- Aug 6, 2007
West-Ward Pharmaceutical — Marketing Organization
- Aug 6, 2007
Wockhardt — Marketing Organization
- Aug 6, 2007
Dr. Reddy's Laboratories — Marketing Organization
- Aug 6, 2007
Daiichi Sankyo — Marketing Organization
- Mar 18, 2008
Amneal Pharmaceuticals — Marketing Organization
- Mar 18, 2008
Sun Pharmaceuticals — Marketing Organization
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
- Jan 1, 2009
Earliest Phase 3 Sponsor(trial)
- Dec 2, 2009
Hikma — Marketing Organization
2010s
- Jun 8, 2010
Mylan — Marketing Organization
- Jun 8, 2010
PHARMOBEDIENT — Marketing Organization
- Jan 1, 2012
Earliest Phase 2 Sponsor(trial)
2020s
- Nov 5, 2020
Sedor Pharmaceuticals — Marketing Organization
- Nov 5, 2020
Lupin — Marketing Organization
- Nov 5, 2020
Lupin — NDA Secondary Org
- Oct 13, 2023
Gland Pharma Ltd — Marketing Organization
Indications
Approved for
Studied for
- Astrocytoma · Phase 1
- Brain Injuries · Phase 4
- Brain Injuries, Traumatic · Phase 4
- Brain Ischemia · Phase 4
- Cancer Pain · Phase 2
- Coma · Phase 4
- Dermatitis, Atopic · Phase 1/Phase 2
- Drugs, Investigational · Phase 3
- Glioblastoma · Phase 1
- Glioma · Phase 1
- Gliosarcoma · Phase 1
- Heart Arrest · Phase 4
- Hypoxia, Brain · Phase 4
- Hypoxia-Ischemia, Brain · Phase 4
- Intracranial Hemorrhages · Phase 4
- Oligodendroglioma · Phase 1
- Persistent Vegetative State · Phase 4
- Seizures · Phase 4
- Status Epilepticus · Phase 4
- Stroke · Phase 4
- Varicella Zoster Virus Infection · Phase 3
Mechanism of action
- Sodium channel alpha subunitBLOCKER
Sodium channel alpha subunit blocker
- Sodium channel protein type 1 subunit alpha (SCN1A) ↗
- Sodium channel protein type 5 subunit alpha (SCN5A) ↗
- Sodium channel protein type 4 subunit alpha (SCN4A) ↗
- Sodium channel protein type 7 subunit alpha (SCN7A) ↗
- Sodium channel protein type 2 subunit alpha (SCN2A) ↗
- Sodium channel protein type 9 subunit alpha (SCN9A) ↗
- Sodium channel protein type 3 subunit alpha (SCN3A) ↗
- Sodium channel protein type 11 subunit alpha (SCN11A) ↗
- Sodium channel protein type 8 subunit alpha (SCN8A) ↗
- Sodium channel protein type 10 subunit alpha (SCN10A) ↗
- Sodium channel protein type I alpha subunit
- Sodium channel protein type V alpha subunit
- Sodium channel protein type IV alpha subunit
- Sodium channel protein type VII alpha subunit
- Sodium channel protein type IX alpha subunit
- Sodium channel protein type II alpha subunit
- Sodium channel protein type III alpha subunit
- Sodium channel protein type XI alpha subunit
- Sodium channel protein type VIII alpha subunit
- Sodium channel protein type X alpha subunit
- Sodium channel alpha subunits; brain (Types I, II, III)
Approval history
- approvedAug 5, 1996
Chemistry & pharmacology
SMILES
O=C1NC(c2ccccc2)(c2ccccc2)C(=O)N1COP(=O)(O)O- Mol. weight
- 362.28 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- ChEMBLCHEMBL1201336 ↗
- WikipediaFosphenytoin ↗
- ChEMBLCHEMBL919 ↗
Also known as
- 2,4-imidazolidinedione, 5,5-diphenyl-3-((phosphonooxy)methyl)-, (sp-4-2)-
- 3-(hydroxymethyl)phenytoin disodium phosphate
- 3-(hydroxymethyl)phenytoin phosphate ester
- (3-phosphoryloxymethyl)phenytoin
- (3-phosphoryloxymethyl)phenytoin
- acc 9653
- acc-9653
- acc-9653-010
- acc-9653-010
- cerebyx
- cerebyx
- cerebyx
- cerebyx
- cerebyx
- ci-982
- ci-982
- fosfenitoina
- fosfenitoina
- fosphenytoin
- fosphenytoin
- fosphenytoin
- fosphenytoin
- fosphenytoin
- fosphenytoin
- fosphenytoin
- fosphenytoin
- fosphenytoin
- fosphenytoin
- fosphenytoin, disodium salt
- fosphenytoine
- fosphenytoine
- fosphenytoin sodium
- fosphenytoin sodium
- fosphenytoin sodium
- fosphenytoin sodium
- fosphenytoin sodium
- fosphenytoin sodium hydrate
- fosphenytoinum
- fosphenytoinum
- hmpdp
- kp-413
- prodilantin
- pro-epanutin
- pro-epanutin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06081283 | Phase 4 | Nov 20, 2023 | University of North Carolina at Chapel Hill |
| NCT06403150 | Phase 4 | May 15, 2023 | Dhaka Medical College |
| NCT05480553 | Phase 3 | Aug 5, 2022 | Nobel Pharmaceuticals |
| NCT04139330 | Phase 2 | Oct 25, 2019 | Nobel Pharmaceuticals |
| NCT03773055 | Phase 2 | Apr 3, 2019 | Nobel Pharmaceuticals |
| NCT01960075 | Phase 3 | Oct 1, 2015 | Children's National Medical Center, Medical University of South Carolina, National Institute of Neurological Disorders and Stroke (NINDS), University of Michigan, University of Minnesota, University of Virginia |
| NCT01870024 | Phase 3 | Jun 1, 2013 | University of Paris |
| NCT01458522 | Phase 2 | May 1, 2012 | Duke University, Hoosier Cancer Research Network |
| NCT01110187 | N/A | May 1, 2010 | Hoosier Cancer Research Network, University of Alabama, Birmingham, University of Cincinnati |
| NCT00932074 | Phase 1/Phase 2 (Phase 2) | Jul 1, 2009 | Dow Pharmaceutical Sciences, Kaken Pharmaceutical Co.,Ltd. |
| NCT00734864 | Phase 1 | Jun 1, 2009 | Bristol-Myers Squibb, Duke University |
| NCT00908453 | Phase 3 | May 1, 2009 | National Center of Neurology and Psychiatry, Japan, Nobel Pharmaceuticals |
| NCT00510783 | Phase 4 | Jul 1, 2007 | Emory University, Hoosier Cancer Research Network |
Organizations
Research & Development (19)
Marketing (29)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Amneal Pharmaceuticals | For profit | MKTG | Mar 18, 2008 |
| Amneal Pharmaceuticals | For profit | SYN | Mar 18, 2008 |
| Apotex | For profit | MKTG | Aug 6, 2007 |
| Atlantide Pharmaceuticals | For profit | MKTG | Aug 6, 2007 |
| Daiichi Sankyo | For profit | MKTG | Aug 6, 2007 |
| Dr. Reddy's Laboratories | For profit | MKTG | Aug 6, 2007 |
| Fresenius | For profit | MKTG | Aug 6, 2007 |
| Gland Pharma Ltd | For profit | MKTG | Oct 13, 2023 |
| Gland Pharma Ltd | For profit | SYN | Oct 13, 2023 |
| Hikma | For profit | MKTG | Dec 2, 2009 |
| Hikma | For profit | SYN | Aug 6, 2007 |
| Hikma | For profit | SYN | Aug 6, 2007 |
| Hospira | For profit | MKTG | Aug 6, 2007 |
| Lupin | For profit | MKTG | Nov 5, 2020 |
| Lupin | For profit | NDA2 | Nov 5, 2020 |
| Lutipold | For profit | MKTG | Aug 6, 2007 |
| Mylan | For profit | MKTG | Jun 8, 2010 |
| PHARMOBEDIENT | For profit | MKTG | Jun 8, 2010 |
| Parke-Davis | For profit | NDA | Aug 5, 1996 |
| Parke-Davis | For profit | NDA2 | Aug 5, 1996 |
| Sankyo | For profit | MKTG | Aug 6, 2007 |
| Sedor Pharmaceuticals | For profit | MKTG | Nov 5, 2020 |
| Sun Pharmaceuticals | For profit | MKTG | Mar 18, 2008 |
| Sun Pharmaceuticals | For profit | SYN | Mar 18, 2008 |
| Teva | For profit | MKTG | Aug 6, 2007 |
| Warner Lambert | For profit | NDA2 | Aug 5, 1996 |
| West-Ward Pharmaceutical | For profit | MKTG | Aug 6, 2007 |
| Wockhardt | For profit | MKTG | Aug 6, 2007 |
| Wockhardt | For profit | SYN | Aug 6, 2007 |